滤网式脑保护装置下颈动脉狭窄支架置入术的临床研究

目的探讨颈动脉支架置入术中滤网式脑保护装置的有效性及安全性。方法19例颈动脉狭窄患者在滤网脑保护装置下使用自膨胀支架行颈动脉支架置入术。观察脑栓塞的发生和所回收的过滤网。术后短期随访。结果19例滤网式脑保护装置下颈动脉支架置入术均成功实施,回收的过滤伞中8个发现组织碎片,无手术死亡及症状性脑梗塞并发症。临床短期随访无脑缺血发生。结论脑保护装置下支架置入术治疗颈动脉狭窄是安全和有效的。     

基于美军二战海战减员数据的校正

目的：通过对二战减员数据的校正，为下一步建立海战减员预计模型提供数据支持．方法：选取美军在二战太平洋海战中的减员数据作为研究的基本资料，通过专家咨询法(Delph method)对其进行校正，所有结果都对其进行了t检验．结果：水面舰艇遭受炸弹、舰炮及航空火炮、短程导弹、鱼雷和水雷的攻击时减员将减少，遭受中程导弹攻击时减员将会增加．结论：该校正结果可作为研究未来海战卫生减员预计的基本依据之一．     

Stargardt病的眼底表现及眼底荧光血管造影特征

目的研究Stargardt病(Stargardts disease,STGD)的眼底表现和眼底荧光血管造影(fundus fluorescein angiography,FFA)的特征.方法对27例54眼STGD患者进行视力、眼底及FFA检查.结果STGD患者的视力在0.02～0.10者46眼,占85.2%.眼底检查黄斑部均有横径为1.5～3.0 PD大小、呈青灰色并有金箔样反光的横椭圆形萎缩灶,其中15例30眼伴有眼底黄色斑点,占55.6%.FFA检查黄斑部病变为透见荧光,其中8例16眼呈"牛眼"状;22例44眼呈暗脉络膜背景,占81.5%.结论FFA检查在STGD的诊断中极为重要,在病程的不同阶段可有不同FFA表现.     

端粒酶活性检测在乳腺癌诊断中的意义

[目的 ]探讨细针穿刺乳腺肿瘤组织的端粒酶活性检测在乳腺癌诊断中的意义 .[方法 ]用聚合酶链反应 酶联免疫吸附测定法检测 79例术前乳腺肿瘤细针穿刺活检标本和大体标本的端粒酶活性 ,并与病理诊断进行比较 .[结果 ]乳腺癌 6 5例中穿刺组织端粒酶呈阳性的为 5 7例 ,阳性率为 88% ;大体组织端粒酶呈阳性的为 5 4例 ,阳性率为 83% .淋巴结转移者端粒酶活性高于无淋巴结转移者 .乳腺良性疾病 14例中端粒酶呈阳性的为 2例 ,阳性率为 14 % .[结论 ]术前乳腺肿瘤穿刺组织的端粒酶活性检测有利于乳腺肿瘤的早期诊断及鉴别诊断 .     

气流粉碎机用蒸汽加料器设计参数研究

对适用于气流粉碎机的蒸汽输送喷射器的设计理论及计算方法作了详细的研究，为气流粉碎机加料器的设计提供了有用的工具。     

高致病性禽流感病人救治管理探讨

2005年至2006年间，在皖南休宁县和屯溪区农村集中网报并纳入特殊疾病救治的有3个病人，其中确诊为人感染高致病性禽流感（H5N1）2例，救治成功1例。对前后3例的救治情况比较研究，认为人感染高致病性禽流感病人救治管理的核心环节有三：一是提高居民的择医意识，及时到专科诊治是救治成功的前提；二是提高基层医生专业知识水平，及时发现及时转医是核心环节；三是提高医院专科的救治能力，制订切实可行的应急预案，优化救治队伍，做出快速的反应，做到有效施治是救治成功的保证。     

实验性腹主动脉瘤瘤体外径与iNOS相关性分析及分期研究

Objective To construct new model of experimental abdominal aortic aneurysm (AAA) and detect the AAA outer diameter and the change of induce nitric oxide synthase(iNOS) in the abdominal aor-tic aneurysm in different period,and analysis the correlation between experimental AAA and iNOS.Methods During the operation of the experiment group,the vascular prosthesis of PTFE was implanted to the rabbit abdominal aorta to form an aneurysm,while sham operation was done in the control group.The tissue of ab-dominal aortic aneurysm was harvested in 1 d,7d,14d,and 28d after operation,respectively.The tissue bo-mogenate concentration of iNOS in the abdominal aortic aneurysm were detected by enzyme linked immu-nosorbent assay (ELISA).Results In experimental group,mean concentration of the tissue bomogenate concentration of iNOS in the abdominal aortic aneurysm in 1 d,7 d,14 d,28 d were (22.129 ±2.518)μ/mL,(27.337±5.321) μ/mL,(36.047±4.584)μ/mL,(44.756±1.799)μ/mL,respectively;In control group,that was (12.499±1.807)μ/mL.The concentration of iNOS in experimental group was significantly higher than that of control group (P < 0.01).The difference during the experimental group all had statisti-cal significance (P < 0.05).Conclusion It is possible that iNOS has some biological function during the formation and progression of the abdominal aortic aneurysm.     

Fabrication of porous hollow silica nanoparticles and their applications in drug release control.

Preparation and characterization of porous hollow silica nanoparticles (PHSN) for controlled release applications were investigated. Through orthogonally designed experiments, the optimal synthesis conditions for the preparation of PHSN were obtained and the produced PHSN were characterized by BET, SEM, TEM and IR. Scanning and transmission electron microscopy images revealed their hollow shell-core structure and also demonstrated that the size and shape of PHSN are determined by the templating CaCO3 nanoparticles. The produced PHSN were applied as a carrier to study the controlled release behaviors of Brilliant Blue F (BB), which was used as a model drug. Being loaded into the inner core and on the surfaces of the nanoparticles, BB was released slowly into a bulk solution for about 1140 min as compared to only 10 min for the normal SiO2 nanoparticles, thus exhibited a typical sustained release pattern without any burst effect. In addition, higher BET of the carriers, lower pH value and lower temperature prolonged BB release from PHSN, while stirring speed showed little influence on the release behavior. It showed that PHSN have a promising future in controlled drug delivery applications.     

心肌肌钙蛋白Ⅰ(cTnⅠ)提纯及ELISA的建立

目的心肌肌钙蛋白Ⅰ(cardiactroponinⅠ,cTnⅠ)的提纯及酶联免疫分析方法的建立。方法从猝死健康人心脏中,提取人心肌肌钙蛋白Ⅰ作为抗原,用其免疫新西兰雌性大耳白家兔,制备出抗人心肌肌钙蛋白Ⅰ抗体,采用夹心方法,建立cTnⅠ酶联免疫吸附分析法。结果从人心肌中提取出11.7mgcTnⅠ,心肌肌钙蛋白Ⅰ抗血清滴度达1∶100000,Ka=2.38×109Lm/ol。方法学指标:灵敏度为0.2ngm/l;精密度,批内、批间变异系数分别为CV=3.8%和CV=8.2%;准确度,平均回收率99.7%;特异性,与心肌肌钙蛋白T、心肌肌钙蛋白C、肌酸磷酸激酶(CK)、肌酸磷酸激酶同工酶(CK-MB)均无交叉反应。用该方法和进口试剂盒对32例急性心肌梗死(AMI)患者和40例健康人血中cTnⅠ水平进行检测,两者符合率分别为93.7%、95.0%。结论该方法适于临床常规检验及科研工作需要,具有广泛应用前景。